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intervention on the human gut resistome 
 
Maho Yokoyama1, Leon Peto2, A. Sarah Walker2, Martin J. Llewelyn1 
Antimicrobials are vital for modern medicine. Antimicrobial use selects for antimicrobial resistant bacteria, particularly among the gut microflora. Minimising 
antimicrobial resistance (AMR) selection by avoiding unnecessary antibiotic use helps combat AMR. Metagenomic analyses have the potential to provide 
accurate detection and quantification of AMR genes within an individual’s gut microbiome (gut ‘resistome’), allowing the impact of different types of antibiotic 
exposures to be evaluated and guide interventions to reduce AMR. 
We have developed a short-read sequencing approach to characterise the gut resistome and piloted this in two clinical sample sets. 
ACLOD Cohort (Journal of Infection (2017)  75, 20-25) 
ARK Cohort 
Conclusions 
 Participants for this study were patients admitted to elderly medicine wards at three UK hospitals; criteria included being over 18 and being negative 
for C. difficile infection.  
 After consenting, participants were asked to provide weekly stool samples during their hospital stay.  
 From those collected, we sequenced two samples from 25 participants at two of the hospitals (n=50). 
 Antibiotic Review Kit (ARK) is a behavioural intervention which aims to aid healthcare workers to reduce unnecessary antibiotic use in hospitals. 
 The impact of the ARK intervention on the human gut resistome is being analysed by utilising discards from diarrhoeal samples which were sent to 
the microbiology lab for C. difficile testing at a UK hospital (n=83), collected before and after the ARK intervention was implemented there.  
Fig. 3 shows how the AMR gene reads/kb/million total reads (RPKM) 
changes over the sample collection period. 
 There seems to be an increase in AMR gene RPKM over time.  
 Month 5, one month after ARK implementation, there is a drop in 
AMR gene RPKM. 
Fig. 4 shows how the frequency of selected AMR genes change over time. 
 There are variations in how the frequency of AMR genes changes over 
the course of sample collection (14 months). 
 However, small sample numbers at each time point (n=5 to 7) makes it 
difficult to draw meaningful conclusions about the changes.  
Fig. 1 shows changes in 
the number of AMR 
gene reads/kb/million 
total reads (RPKM, A) 
and AMR gene number 
(B) 
 There is no significant 
association between 
length of hospital 
stay and AMR gene 
carriage. 
Fig. 2 shows which AMR genes 
were most frequently seen in the 
first sample (01) and second 
sample (02) 
 tetW (88%) is the most frequent 
in the first sample, while dfrF 
(88%) is the most frequent in 
the second.  
 There seems to be more AMR 
genes present in the second 
sample compared to the first. 
Further work  Direct, deep sequencing can be used to detect AMR genes in faecal samples. 
 Longer hospital stays do not show a statistically significant difference in 
AMR gene RPKM/number, but more data may reveal an effect.  
 AMR gene RPKM seems to increase in the ARK cohort, but is difficult to 
conclude due to the low sample numbers and high variability.  
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Bioinformatics Analysis  
 Remove sequencing adaptors and low-quality / human reads. 
 Match the cleaned sequencing reads to known AMR genes in CARD database (DOI: 
10.1093/nar/gkw1004) using the programme ARIBA (DOI: 10.1099/mgen.0.000131) 
     - this determines what AMR genes are present in each sample.  
 Apply a regression model to the ACLOD data, as an alternative method to look 
at the changes in AMR gene carriage over hospital stay.  
 More samples from this ARK cohort, as well as those from two other “ARK 
participating hospitals”, will be analysed to add to the existing dataset.  
 Perform an interrupted time series analysis to see if the ARK intervention 
slows down the increase in AMR genes seen in this cohort.  
Figure 1: changes in AMR gene reads/kb/million total reads (RPKM, A) 
and AMR gene number (B) between the first and second samples from each 
patient, with Spearman’s correlation (n=25). 
Figure 2: the frequency of AMR genes 
in the first (01) and second (02) samples 
(n=25 for each time point).  
Sequence to a depth 
of ~10 million reads 
ARK implemented Figure 3: changes 
seen in AMR gene reads/
kb/million total reads 
(RPKM) before and after 
the implementation of 
the ARK intervention at 
a UK hospital (n=5 to 7 
for each month). 
Figure 4: changes in the 
frequency of selected AMR genes 
over the sample collection period 
(14 months, n=5 to 7 for each 
month). Black lines indicate when 
the ARK intervention was 
implemented.  
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